Previous findings in Smith’s laboratory suggest that an insulinlike growth factor 1 receptor (IGF-1R) plays an important role in Graves’ disease and other autoimmune diseases.
...Study investigators examined the benefit of teprotumumab, a monoclonal antibody shown to inhibit IGF-1 function. It was originally developed as a cancer drug. Although teprotumumab failed to exhibit efficacy in patients with cancer, the team thought it might be useful in interrupting the TED disease process. At the end of the trial, 69 percent of study patients receiving infusions of teprotumumab once every three weeks had reduced eye bulging (proptosis), improved vision and increased quality of life compared with 20 percent in the placebo group.
...Many participants showed improvement within six weeks when, according to the study, a reported 43 percent of patients in the treatment group had a response, compared with 4 percent in the placebo group.